Currently submitted to: JMIR Preprints
Date Submitted: Jun 13, 2020
Open Peer Review Period: Jun 12, 2020 - May 28, 2021
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer-review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer-Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Viewpoint_SARS-CoV-2 Biology Suggests We Should Protect Our Young Population
ABSTRACT
Background:
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was initially known as a virus causing flu-like symptoms, or sometimes pneumonia. Thus, when the World Health Organization (WHO) declared COVID-19 pandemic and suggested lockdown measures, the apparently disproportionate measures were viewed as an inconsistency, raising the question whether measures were exaggerated or the virus was more dangerous than it had been publicly stated.
Objective:
The initial objective was to resolve or understand that inconsistency.
Methods:
As every day counts during an emergency, and there were so many unanswered questions, not only scientific papers but also pre-prints, institutional webpages, newspapers, cruise registers, projects and patents were critically used as information sources and are identified as such. The biology of SARS-CoV-2 was compared to that of SARS and other coronaviruses in order to gain insights.
Results:
COVID-19 is a systemic disease. There is at least one detection report of SARS-CoV-2 in human samples of blood, stool, urine, cerebrospinal fluid, and sperm. Like HIV, SARS-CoV-2 can damage the immune system directly. Like other coronaviruses, SARS-CoV-2 can infect the brain and might contribute to neurodegeneration. Growing evidence indicates that SARS-CoV-2 can establish a persistent infection, with alternating waves of convalescence and recurrence. In addition, even rare latency with ulterior reactivation has not been discarded. SARS-CoV-2 exploits antibody-dependent enhancement (ADE), like Dengue and SARS-CoV. For this reason, it is unlikely that a successful vaccine will be developed. However, there are promising therapeutic alternatives. Host cell targets could be modulated to hamper viral replication, but targeting viral proteins directly would be a better therapeutic design, since fewer adverse side effects would be expected.
Conclusions:
SARS-CoV-2 name turned out to be inadequate, since this virus is systemic and can persist, affecting most body systems including the immune and the nervous system. This virus is very likely to have long-term effects. According to our current knowledge state (and gaps),infected asymptomatic people should be considered not just as a carrier of a virus that affects the elderly or immune-compromised individuals, but as potential hosts and victims of a persistent/long-term systemic infection. For this reason, we should encourage protection measures towards the young population before it is too late. As lockdown is not a life option, more measures to minimize viral spreading could be adopted, particularly regarding babies, children, adolescents and young adults. There fortunately are promising therapeutic strategies to be developed.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.